GCF LEVELS OF sRAGE AND MCP-1 IN TYPE-2 DIABETIC PATIENTS WITH PERIODONTITIS: A PRELIMINARY REPORT

Year 2024, Volume: 48 Issue: 3, 133 - 139, 20.12.2024

Yağmur Deniz Yıldırım , Esra Ercan , Güliz Nigar Güncü , Erdem Karabulut , Ayşe Ezel Berker

Abstract

Background and Aim: Diabetes mellitus-related chronic complications can affect multiple organs, including the macrovascular and microvascular systems, as well as the periodontium. Advanced glycation end products (AGE), its receptor (RAGE) and soluble receptor (sRAGE) interaction is critically involved in the pathobiology of both diseases. Monocyte chemoattractant protein-1 (MCP-1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. This study aimed to compare the levels of MCP-1 and sRAGE in the gingival crevicular fluid (GCF) of periodontitis patients with type 2 diabetes and those without, hypothesizing that these levels may vary based on diabetic status.
Materials and Methods: Nine patients with periodontitis and diabetes (DP), 12 periodontitis (P) patients without diabetes, 12 systemically and periodontally healthy subjects (HC) were enrolled in this case-control study. Clinical periodontal parameters and HbA1c values were evaluated. Gingival crevicular fluid samples were analysed for sRAGE and MCP-1 by an enzyme-linked immunosorbent assay. The significance of differences were assessed with Kruskall-Wallis test. Pairwise
comparisons were made with Dunn test.
Results: sRAGE and MCP-1 levels were significantly higher in periodontitis group than healthy controls (p<0.05). There was no difference between DP and P groups (p>0.05). Positive correlation was detected between sRAGE and MCP-1 levels in disease groups (p=0.000, r=0.976 for DP group; p=0.000, r=0.982 for P group respectively).
Conclusion: MCP-1 and sRAGE may have a functional role in the diabetic-periodontal pathogenesis. Further studies must be carried out to understand the contribution of sRAGE and MCP-1 in periodontal inflammation with or without diabetes.

Keywords

GCF , Periodontitis , sRAGE , MCP-1 , Type 2 Diabetes

References

• 1. Lamster IB, Novak MJ. Host mediators in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. Crit Rev Oral Biol Med 1992; 3: 31-60.
• 2. Pradeep AR, Daisy H, Hadge P. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 in periodontal health and disease. Arch Oral Biol 2009; 54: 503-509.
• 3. Jiang Y, Graves DT. Periodontal pathogens stimulate CCchemokine production by mononuclear and bone-derived cells. J Periodontol 1999; 70: 1472-1478.
• 4. Emingil G, Atilla G, Huseyinov A. Gingival crevicular fluid monocyte chemoattractant protein-1 and RANTES levels in patients with generalized aggressive periodontitis. J Clin Periodontol 2004; 31: 829-834.
• 5. Kurtis B, Tuter G, Serdar M, Akdemir P, Uygur C, Firatli E et al. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. J Periodontol 2005; 76: 1849-1855.
• 6. Hanazawa S, Kawata Y, Takeshita A, Kumada H, Okithu M, Tanaka S et al. Expression of monocyte chemoattractant protein 1 (MCP- 1) in adult periodontal disease: increased monocyte chemotactic activity in crevicular fluids and induction of MCP-1 expression in gingival tissues. Infect Immun 1993; 61: 5219-5224.
• 7. Nishimura F, Takahashi K, Kurihara M, Takashiba S, Murayama Y. Periodontal disease as a complication of diabetes mellitus. Ann Periodontol 1998; 3: 20-29.
• 8. Schmidt AM, Weidman E, Lalla E, Yan SD, Hori O, Cao R et al. Advanced glycation endproducts (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with diabetes. J Periodontal Res 1996; 31: 508-515.
• 9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
• 10. Welsh KJ, Kirkman MS, Sacks DB. Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions. Diabetes Care, 2016; 39: 1299-1306.
• 11. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-114.
• 12. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79: 1527-1534.
• 13. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010; 5: 19-28.
• 14. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54: 1615-1625.
• 15. Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. Periodontol 2000; 23: 50-62.
• 16. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 2005; 32: 40-44.
• 17. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
• 18. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313.
• 19. I Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-287.
• 20. Singhal S, Pradeep AR, Kanoriya D, Garg V. Human soluble receptor for advanced glycation end products and tumor necrosis factor-alpha as gingival crevicular fluid and serum markers of inflammation in chronic periodontitis and type 2 diabetes. J Oral Sci 2016; 58: 547-553.
• 21. Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri- Implant Diseases and Conditions. J Periodontol 2018; 89: 173-182.
• 22. Loe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol 1967; 38: 610-616.
• 23. Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem 2018.
• 24. Santilli F, Bucciarelli L, Noto D, Cefalu AB, Davi V, Ferrante E et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007; 43: 1255-1262.
• 25. Kim KS, Lee YJ, Ahn S, Chang YS, Choi Y, Lee HJ. Association between soluble forms of the receptor for advanced glycation end products and periodontal disease: a retrospective study. J Korean Assoc Oral Maxillofac Surg 2021; 47: 445-453.
• 26. Detzen L, Cheng B, Chen CY, Papapanou PN, Lalla E. Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis. Sci Rep 2019; 9: 8170.
• 27. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62: 2116-2121.
• 28. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005; 51: 1749-1750.
• 29. Fujisawa K, Katakami N, Kaneto H, Naka T, Takahara M, Sakamoto F et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013; 227: 425-428.
• 30. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411.
• 31. Prasad K, Sarkar A, Zafar MA, Shoker A, Moselhi HE, Tranquilli M et al. Advanced Glycation End Products and its Soluble Receptors in the Pathogenesis of Thoracic Aortic Aneurysm. Aorta (Stamford) 2016; 4: 1-10.
• 32. Sakallioglu EE, Ayas B, Lutfioglu M, Keles GC, Acikgoz G, Firatli E. Gingival levels of monocyte chemoattractant protein-1 (MCP-1) in diabetes mellitus and periodontitis: an experimental study in rats. Clin Oral Investig 2008; 12: 83-89.
• 33. Gemmell E, Carter CL, Seymour GJ. Chemokines in human periodontal disease tissues. Clin Exp Immunol 2001; 125: 134- 141.
• 34. Yu X, Antoniades HN, Graves DT. Expression of monocyte chemoattractant protein 1 in human inflamed gingival tissues. Infect Immun 1993; 61: 4622-4628.
• 35. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-1127.
• 36. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
• 37. Mine S, Okada Y, Tanikawa T, Kawahara C, Tabata T, Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 2006; 344: 780-785.